期刊文献+

吡格列酮对新诊断2型糖尿病患者血清C反应蛋白的影响 被引量:4

下载PDF
导出
摘要 目的探讨吡格列酮对新诊断2型糖尿病患者血清C反应蛋白的影响。方法将50例新诊断的2型糖尿病患者随机分成2组,治疗组26例予盐酸吡格列酮15mg/d,对照组24例予除噻唑烷二酮类和二甲双胍以外的其他降糖药物治疗6个月。结果治疗组治疗后的C反应蛋白、胰岛素抵抗指数和空腹胰岛素水平较对照组低(P〈0.01),胰岛素敏感指数较对照组高(P〈0.01)。结论吡格列酮可以增加2型糖尿病患者的胰岛素敏感性,改善胰岛素抵抗,降低C反应蛋白,减轻炎症反应。
出处 《临床内科杂志》 CAS 2010年第2期123-124,共2页 Journal of Clinical Internal Medicine
  • 相关文献

参考文献7

  • 1Pickup JC, Crook MA. Is type 2 diabetes mellitus a disease of innate immune system? Diabetologia,1998 ,41:1241-1248.
  • 2Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glacosedisorders in the elderly: the cardiovascular health study. Diabetes ,2001,50:2384-2389.
  • 3Martens FM, Visseren FL, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs ,2002,62 : 1463-1480.
  • 4Satoh, Noriko MD, Ogawa, et al. Antiatherogenic Effect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic Effect. Diabetes Care.2003.26.2493-2499.
  • 5Ridker PM, Rifal N, Rose L, et al. Comparison of C-creactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med ,2002,347 : 1557-1565.
  • 6Masabiko L, akihiko H, Hiroshi Y, et al. Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients. J Atheroscler Thromb, 2008, 15:34-40.
  • 7Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60 : risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke ,2002,33 : 1776-1781.

同被引文献16

  • 1罗丹,鄢盛恺,程歆琦,宋耀虹.2型糖尿病合并冠心病患者的同型半胱氨酸水平及代谢关键酶基因多态性特点[J].卫生研究,2009,38(1):39-42. 被引量:10
  • 2姚晓爱,许樟荣,王玉珍,焦凯,伍春荣,史琳涛,胡莲娜,倪彩虹.2型糖尿病患者治疗3年前后临床疗效对比分析[J].中国实用内科杂志,2007,27(15):1196-1198. 被引量:14
  • 3Chiquette E, Ramirez G, Defronzo R. A recta-analysis comparing the effect of thiazolidinediones on cardlovascular risk factors [J]. Arch Intern Med. 2004,164(19) :2097-2104.
  • 4Benton CR, Holloway GP, Campbell SE, et al. Rosiglitazone increases fatty acid oxidation and fatty acid translocase (FAT/ CD36) but not carnitine palmitoyltransferase I in rat muscle mitochondrla [J].Physiol. 2008, 15(6) : 1755-1766.
  • 5Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus[J]. Ann Intern Med, 2007,147(6) : 386-399.
  • 6Gastaldelli, A. , Casolaro, A. , Pettiti, et al. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes [J]. Clinical Pharmacology and Therapeutics, 2007,81 (2) :205-212.
  • 7Schernthaner G, Forst T, Gulba D, et al. Challenge in diabetes therapy: effects of glitazones beyond blood glucose control[J] . Dtsch Med Wochenschr, 2009,134(18):949-954.
  • 8Martens FM,Visseren FL,Lemay J,et al.Metabolic and additional vascular effect of thiazolidinesdiones[J].Drug,2002,62:1463-1480.
  • 9Hayakawa T,Shiraki T,et al.Pioglitazone improves insulin signs ling defects in skeletal from wistar fatty(fa/fa)rats[J].Biechem Biophys Bes Commun,1996,223:439.
  • 10Ridker PM,Rifal N,Rose L,et al.Comparison of C-creactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events[J].N Engl J Med,2002,347:1557-1565.

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部